KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Kirsten rat sarcoma virus (KRAS) gene mutations, particularly KRASG12D, are prevalent in pancreatic ductal adenocarcinomas (PDAC).
• PDAC with KRASG12D mutations often exhibits aggressive phenotypes, increased lymphatic networks, and lymph node (LN) metastasis.

Purpose of the Study:

• To investigate the mechanistic link between KRASG12D mutation and lymphangiogenesis in PDAC.
• To elucidate the pathway by which KRASG12D influences lymphatic vessel formation and metastasis.

Main Methods:

• Utilized in vitro and in vivo models of PDAC.
• Employed mechanistic studies to identify molecular players involved in KRASG12D-mediated lymphangiogenesis.
• Investigated the role of SUMOylation, extracellular vesicles (EVs), and hnRNPA1 in the process.

Main Results:

• KRASG12D mutation induces SUMOylation of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) via SAE1 and SUMO2.
• SUMOylated hnRNPA1 is packaged into EVs and internalized by human endothelial lymphatic cells (HLEC).
• SUMOylated hnRNPA1 stabilizes prospero homeodomain protein 1 (PROX1) mRNA, promoting lymphangiogenesis and LN metastasis.

Conclusions:

• Established an alternative pathway for lymphangiogenesis promotion driven by KRASG12D.
• Identified SUMOylated hnRNPA1 as a key mediator in KRASG12D-associated lymphangiogenesis and metastasis.
• Highlighted the potential for developing novel biomarkers and RAS pathway therapeutics for PDAC.